Interview with:
Interview by:

Mohammed Milhem on the combination of CMP-001 + Pembro

Mohammed Milhem presents preliminary data on the combination of the TLR9 agonist CMP-001 and pembrolizumab in patients with metastatic melanoma resistant to anti-PD-1.

Mohammed Milhem, MBBS, clinical professor of internal medicine at the University of Iowa, Iowa City presents preliminary data from an ongoing phase Ib clinical trial in which patients with metastatic melanoma resistant to PD-1-checkpoint-inhibition were given a combination of CMP-001, an intratumoral Toll-like receptor 9 (TLR9) agonist, and pembrolizumab.

Milhem M. et al, abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma